DMAA Financials

Income Statement
MetricQ2 2026Q1 2026Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
136.9K
-4.4%
143.3K
-45.7%
263.7K
+99.9%
131.9K
-60.1%
330.9K
R&D
0
0
0
0
0
SG&A
136.9K
-4.4%
143.3K
-45.7%
263.7K
+99.9%
131.9K
-60.1%
330.9K
Operating Income
-136934
+4.4%
-143301
+45.7%
-263703
-99.9%
-131919
+60.1%
-330925
EBITDA
-136934
+4.4%
-143301
+45.7%
-263703
-99.9%
-131919
+60.1%
-330925
Net Income
1.7M
-12.4%
2.0M
-9.8%
2.2M
-4.5%
2.3M
+82.4%
1.3M
EPS (Basic)
$0.06
+0.0%
$0.06
-14.3%
$0.07
+0.0%
$0.07
+40.0%
$0.05
EPS (Diluted)
$0.06
+0.0%
$0.06
-14.3%
$0.07
+0.0%
$0.07
+40.0%
$0.05
Shares (Diluted)
30.8M
-8.6%
33.7M
+0.6%
33.5M
+0.0%
33.5M
+31.4%
25.5M
Drugs Made In America Acquisition (DMAA) โ€” Financials